Grant ID CC121020
Awarded On November 02, 2011
Title Novel targeted biologics, Engineered Toxin Bodies (ETB), as cancer therapeutics
Program Product Development Research
Award Mechanism Company Commercialization
Institution/Organization Molecular Templates, Inc.
Principal Investigator/Program Director Jason Kim
Cancer Sites Lymphoma
Contracted Amount $10,600,000
Lay Summary

There are over 65,000 cases of Non-Hodgkin Lymphoma (NHL) diagnosed in the US each year (SEER Cancer Statistics, 2010). The use of chemotherapy in combination with biologics that target the extracellular B-cell marker CD20 has dramatically improved outcomes in NHL. The five-year survival rate for the disease has risen from 31% in 1960 to 69% in 2006 (The Leukemia and Lymphoma Society, 2010).

Despite these advances in treatment, most patients still relapse; NHL is still associated with significant morbidity and mortality. It is estimated that more than 20,000 patients a year will die from the disease in the US alone, making it the eighth and sixth most common cause of cancer death in males an...

Read More